The KIRA assay was used to assess residual ligand bioactivity in the circulation of IGF-TRAP-treated mice and performed as described in detail elsewhere19,29 including recent modifications30. In brief, HEK293 cells overexpressing IGF-1R were cultured in complete DMEM medium (containing 1% Penicillin/Streptomycin, 0.5 mg/ml G418, 0.25 mg/ml Hygromycin, 10% FCS). The cells were then seeded in a 48-well microtiter plate (4 × 105 cells per well) for 24 h with serum, followed by a 24 h incubation without serum. After 48 h, sera from mice injected with 0.5 or 10 mg/kg IGF-TRAP diluted (1:10) in Krebs Ringer buffer or serially diluted rhIGF-1 (concentrations ranging from 0.3125–10 ng/ml, for standard curve) were added to the cells. Following a 15 min incubation at 37 °C to activate the IGF-1R, the cells are lysed (in HEPES lysis buffer) and the lysate transferred to a microtiter plate pre-coated with an IGF-1R capture antibody (Human phospho-IGF-1R ELISA kit, R&D Systems, Minneapolis, MN) and probed with an HRP-conjugated anti-phospho-tyrosine antibody. IGF-1R activation levels were measured at a wave length of 450 nm. Area under the IGF-1 serum concentration vs time curves up to day 18 were calculated using Phoenix WinNonlin Software v8.0.0.3176 (Pharsight Corporation).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.